The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism

Summary

Patients with a first episode of symptomatic pulmonary embolism (PE) havea higher risk of recurrent venous thromboembolism (VTE) than patients with a first episode of proximal lower extremity deep vein thrombosis (DVT). Patients with symptomatic DVT and silent PE may havea different risk of VTE recurrence than patients that have symptomatic DVT without PE. Therefore, it was the aim of this prospective cohort study to compare the risk of recurrent symptomaticVTE in patients with proximal lower extremity DVT and silent PE to the risk in patients that only have proximal lower extremity DVT. Ninty-one consecutive outpatients presenting to the emergency department of a university hospital subsequently hospitalised with a first episode of unprovoked symptomatic proximal lower extremity DVT, and without new pulmonary symptoms were included. Standard initial treatment consisted of intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin for 5–7 days, overlapped with oral vitamin-K antagonist therapy, with long-term oral vitamin-K antagonist therapy (goal INR 2.5 [2.0–3.0]). Study endpoints were: symptomatic recurrent DVT, new PE, and recurrent PE, evaluated by standard objective testing. At enrolment, 28 of 91 (31%) patients with DVT had silent PE. In the patients with DVT and silent PE, there were 3 VTE recurrences during 20 person-years of follow-up, while there were no VTE recurrences during 61 person-years of follow-up in the patients with isolated DVT. The Kaplan-Meier estimated VTE recurrence rate at 1 year after the diagnosis of DVT was 11% (95% CI: 2–28%) for patients with symptomatic DVT and silent PE, compared to 0% in patients with isolated symptomatic DVT (p = 0.0045). In patients with a first episode of unprovoked symptomatic acute proximal lower extremity DVT, the risk of recurrent VTE was significantly higher in those with silent PE compared to those without PE.

Keywords

Clinical/epidemiological studies - pulmonary embolism - deep vein thrombosis

• References

• 1 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-93.
• 2 Barritt DW, Jordan SC. Anticoagulant drugs in treatment of pulmonary embolism: controlled trial. Lancet 1960; 01: 1309-12.
• 3 Douketis JD, Kearon C, Bates S. et al. Risk of fatal pulmonary embolism in patients treated venous thromboembolism. JAMA 1998; 279: 458-62.
• 4 Moser KM, Fedullo PF, LitteJohn JK. et al. Frequent asymptomatic pulmonary embolism in patients with deep vein thrombosis. JAMA 1994; 271: 223-5.
• 5 Monreal M, Rey-Joly C, Ruiz J, Salvador R. et al. Asymptomatic pulmonary embolism in patients with deep vein thrombosis. Is it useful to take a lung scan to rule out this condition?. J Cardiovasc Surg 1989; 30: 104-7.
• 6 Meignan M, Rosso J, Gauthier H. et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 2000; 160: 159-64.
• 7 Monreal M, Büller H, Lensing AW. et al. Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study. Thromb Haemost 2002; 88: 938-42.
• 8 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
• 9 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
• 10 Pinede L, Ninet J, Duhaut P. et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453-60.
• 11 Büller H, Agnellli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2004; 126: 401S-428S.
• 12 Ridker PM, Goldhaber SZ, Danielson E. et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
• 13 Kearon C, Ginsberg JS, Kovacs MJ. et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
• 14 Eichinger S, Weltermann A, Minar E. et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164: 92-6.
• 15 Koopman M, Prandoni P, Piovella F. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
• 16 Levine M, Gent M, Hirsch J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
• 17 Monreal M, Montserrat E, Salvador R. et al. Realtime ultrasound for diagnosis of symptomatic venous thrombosis and for screening of patients at risk: correlation with ascending conventional venography. Angiology 1989; 40: 527-33.
• 18 PIOPED investigators. Value of ventilation/ perfusion scan in acute pulmonary embolism: results of the prospective investigation of the pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263: 2753-9.
• 19 Remy-Jardin M, Remy J, Wattinne L. et al. Central pulmonary thromboembolism: diagnosis with spiral volumetric CT with the single-breath-hold-technique-comparison with pulmonary angiography. Radiology 1992; 185: 381-7.
• 20 Prandoni P, Cogo A, Bernardi E. et al. A simple approach for detection of recurrent proximal vein thrombosis. Circulation 1993; 88: 1730-5.
• 21 Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: John Wiley & Sons; 1980
• 22 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
• 23 Büller HR, Davidson BL, Decousus H. et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004; 140: 867-73.
• 24 Simonneau G, Sors H, Charbonnier B. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.
• 25 Gould MK, Dembitzer AD, Doyle RL. et al. Lowmolecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med 1999; 130: 800-9.
• 26 Monreal M, Ruiz J, Salvador R. et al. Recurrent pulmonary embolism. A prospective study. Chest 1989; 95: 976-9.
• 27 Perrier A. Deep vein thrombosis and pulmonary embolism. A single disease entity with different risk factors?. Chest 2000; 118: 1235-6.
• 28 Agnelli G, Prandoni P, Becattini C. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139: 19-25.
• 29 Agnelli G. Long-term low-dose warfarin is effective in the prevention of recurrent venous thromboembolism: no. J Thromb Haemost 2004; 02: 1038-40.
• 30 Moser KM, LeMoine JR. Is embolic risk conditioned by localization of deep venous thrombosis?. Ann Intern Med 1981; 94: 439.